Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV

Several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston focused on treating hepatitis C recurrence in liver transplant

Published
1 hour ago
By
Liz Highleyman
FDA declines to approve Bristol-Myers hepatitis drug

Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.

Published
1 hour ago
From
Reuters
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not

Published
2 hours ago
By
Liz Highleyman
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C

An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for

Published
25 November 2014
By
Liz Highleyman
Deaths of Japanese patients prompt label change for simeprevir

The maker of Sovriad (simeprevir) has revised its package insert labeling on the order of Japanese health officials following the deaths of three people who took the hepatitis C drug.

Published
24 November 2014
From
HCP Live
Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead

The fixed price reduced the cost by about 27%, and so a 12-week regimen will now be priced at $51,400, instead of $71,100. This makes this the “lowest price in Europe,” according to the Economic Committee for Health Products. There is also stipulation that rebates will be made in the event of “treatment failure,” according to a statement from the agency.

Published
21 November 2014
From
Wall Street Journal
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response

Published
21 November 2014
By
Liz Highleyman
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes,

Published
19 November 2014
By
Liz Highleyman
NHS asks Nice to delay ground-breaking hepatitis C drug

Nice is due to finish its final assessment of sofosbuvir in January. It is usual for them to give the NHS three months to find the money or put staff – if needed – in place. NHS England is thought to have asked them to delay this by six months.

Published
19 November 2014
From
Channel 4 News (blog)
European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi® in January 2014.

Published
19 November 2014
From
Gilead press release
← First12345...47Next →

Filter by country